No Data
Zhongyuan Xiehe Cell & Gene Engineering Co., Ltd. First Quarter Report for 2026
Summary of the 2025 Annual Report of Zhongyuan Xiehe Cell & Gene Engineering Co., Ltd.
2025 Annual Report of Zhongyuan Xiehe Cell & Gene Engineering Co., Ltd.
Zhongyuan Hehe's net profit attributable to shareholders reached 1.14 billion yuan in 2025, increasing by 13.43%. Testing reagents and cell businesses collectively contributed over 80% of total revenue.
Combined revenue from testing reagents and cell businesses accounted for 84.25% of total revenue, reflecting a continued focus on structural optimization; gross margin in manufacturing increased to 70.01%, with net profit margin rising to 7.82%. Research and development expenses and sales expenses decreased by 18.17% and 12.89%, respectively, while delays were reported across most fundraising projects, indicating a more cautious strategic pace.
Zhongyuan Hehe (600645.SH): Net profit attributable to shareholders in 2025 reached 114 million yuan, representing a year-on-year increase of 13.43%.
Gelonghui, April 24th: Zhongyuan Xiehe (600645.SH) released its 2025 annual report. During the reporting period, the company achieved operating revenue of 1.455 billion yuan, a year-on-year decrease of 8.23%; net profit attributable to shareholders of the listed company was 114 million yuan, a year-on-year increase of 13.43%.
Zhongyuan Xiehe (600645.SH): Net profit attributable to shareholders in Q1 2026 was RMB 24.2449 million, representing a year-on-year decrease of 13.50%.
Gelonghui, April 24th: Zhongyuan Xiehe (600645.SH) announced its Q1 2026 financial report. During the reporting period, the company achieved operating revenue of 317 million yuan, a year-on-year decrease of 9.54%; net profit attributable to shareholders of the listed company was 24.2449 million yuan, a year-on-year decrease of 13.50%.